Lilly wins appeal in patent fight over ADHD drug Strattera
This article was originally published in Scrip
Executive Summary
The US Court of Appeals for the Federal Circuit has upheld the validity of Lilly's method-of-use patent for its attention deficit/hyperactivity disorder drug Strattera (atomoxetine), overturning a district court's ruling that the patent was invalid (scripintelligence, 17 August 2011).